Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MP0310 · 1 trial · 1 indication
According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
Dose-limiting toxicities will be reviewed as a subset of AEs that occur within the first 21 days of dosing and meet the protocol-specified criteria.
Based on occurrence of DLTs within a 3+3 clinical trial design
Based on incidence and nature of DLTs, and incidence, nature, and severity of AEs and serious adverse events (SAEs)
| Arm | Type | Description |
|---|---|---|
| MP0310 Part A | EXPERIMENTAL | Enrollment will follow a standard 3 + 3 dose escalation design. Sequential Cohorts of patients will be dosed until the MTD or unacceptable toxicity is reached. Up to 12 additional patients in total may be included at selected dose levels (up to 3). |
| MP0310 Part B | EXPERIMENTAL | weekly schedule, at least 3 and up to 24 patients evaluable for DLT assessment will be enrolled (1 to 4 cohorts with 3 to 6 patients each (3 initial plus up to 3 backfill patients)). |
| MP0310 Part C | EXPERIMENTAL | q3w schedule implementing B-cell depletion, at least 3 and up to 12 patients evaluable for DLT assessment will be enrolled (1 to 2 cohorts with 3 to 6 patients each (3 initial plus up to 3 backfill patients)). |
| Name | Type | Description |
|---|---|---|
| MP0310 | DRUG | MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors |
Inclusion criteria: 1. Patient has an advanced, histologically-proven solid tumor of one of the following types, treated with at least one line of systemic therapy, and for which approved therapies have been exhausted or for which the Investigator considers the patient ineligible or intolerant of o...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MP0310 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its safety, blood levels, and activity in patients with advanced solid tumors.
MP0310 is being developed by Molecular Partners AG, a biopharmaceutical company. The company's stock is traded under the ticker symbol MOLN. The drug is currently in Phase 1 clinical development for the treatment of advanced solid tumors.
MP0310 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 clinical trial has been completed to investigate the safety, blood levels, and activity of MP0310 in patients with advanced solid tumors.
MP0310 has one completed clinical trial with the identifier NCT04049903. This Phase 1 study investigated the safety, blood levels, and activity of MP0310 in patients with advanced solid tumors. The trial enrolled 38 participants and was conducted in France.
MP0310 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of advanced solid tumors. The drug is being studied for its safety, blood levels, and activity, but has not yet received regulatory approval.